Comparison

Rifapentine-d9 European Partner

Item no. HY-B0269S-1ea
Manufacturer MedChem Express
Amount 1 ea
Quantity options 1 ea 1 mg 5 mg
Category
Type Molecules
Specific against other
Citations [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. |[2]Sharma, S.K., et al., Rifamycins (rifampicin, rifabutin and rifapentine) compared to isoniazid for preventing tuberculosis in HIV-negative people at risk of active TB. Cochrane Database Syst Rev, 2013. 7: p. CD007545.
Smiles OC(C1=C(C2=O)C(O[C@@]2(O/C=C/[C@@H]([C@H]([C@@]([C@@H]3C)([H])OC(C)=O)C)OC)C)=C(C)C(O)=C1C(O)=C4NC(/C(C)=C\C=C\[C@@H]([C@@H]([C@@H](C)[C@H]3O)O)C)=O)=C4/C=N/N5CCN(C6([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])C6([2H])[2H])CC5
ECLASS 10.1 32169090
ECLASS 11.0 32169090
UNSPSC 12000000
Alias DL 473-d9,Cyclopentylrifampicin-d9
Shipping Condition Room temperature
Available
Manufacturer - Type
Isotope-Labeled Compounds
Manufacturer - Targets
Antibiotic; Bacterial; Isotope-Labeled Compounds
Shipping Temperature
Room temperature
Molecular Weight
886.09
Product Description
Rifapentine-d9 is the deuterium labeled Rifapentine. Rifapentine (DL 473) is an antibiotic compound used in the treatment of tuberculosis.
Manufacturer - Research Area
Infection
Solubility
10 mM in DMSO
Manufacturer - Pathway
Anti-infection; Others
Clinical information
No Development Reported

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Amount: 1 ea
Available: In stock
available

Compare

Add to wishlist

Get an offer

Request delivery time

Ask a technical question

Submit a bulk request

Questions about this Product?
 
Close